Ivesk (Ivermectin)

Ivermectin binds to glutamate‑gated chloride channels that are present on the nerve and muscle cells of invertebrates. This binding opens the channels, allowing an influx of chloride ions, which hyperpolarises the cells, causing paralysis and death of the parasite while sparing human cells.

The dose of Ivesk is determined by the prescribing clinician based on the specific indication, the patient’s body weight, age, renal and hepatic function, and any relevant comorbidities. The prescriber follows approved dosing guidelines for each condition.

Safety of ivermectin in pregnancy has not been established, and it is generally avoided unless the potential benefit justifies the risk. During breastfeeding, caution is advised; the drug may be excreted in milk, so the infant should be monitored for adverse effects.

To order Ivesk, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Ivermectin and albendazole belong to different antiparasitic classes; ivermectin is a macrocyclic lactone effective against many nematodes and ectoparasites, while albendazole is a benzimidazole primarily used for tapeworms and some roundworms. Choice of therapy depends on the parasite species, resistance patterns and clinical guidelines.

Ivesk should be stored at ambient temperature below 25 °C. Keep the tablets in the original packaging, protect them from moisture, heat and direct light, and ensure the container is tightly closed to maintain product stability.

Ivesk is taken orally as a tablet with water. The exact timing (with or without food) and the number of doses depend on the indication and the prescriber’s instructions. Patients should follow the dosing schedule provided by their healthcare professional.

Serious risks, although rare, include severe skin reactions such as Stevens‑Johnson syndrome, hepatotoxicity with elevated liver enzymes, neurologic events like seizures or confusion, and significant hypotension or visual disturbances. Patients should seek immediate medical attention if any of these symptoms occur.

Ivesk should be avoided in patients with known hypersensitivity to ivermectin or any excipients, in children weighing less than 15 kg, and in individuals where the risk of adverse effects outweighs the therapeutic benefit, such as certain pregnant women or patients with severe hepatic impairment without appropriate monitoring.